Phase 2 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You (or your child) have been diagnosed with a RASopathy (a group of genetic conditions affecting growth and development)
- You (or your child) have been diagnosed with hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened)
- You (or your child's guardian) are willing and able to sign a consent form to participate
Who may not be able to join:
- You (or your child) cannot take propranolol due to reasons such as an allergy to the drug, certain heart rhythm problems (atrioventricular block), or an unusually slow heart rate (confirm with trial site)
- You (or your child) cannot take disopyramide due to reasons such as an allergy to the drug, a heart condition called WPW syndrome, certain heart rhythm problems (atrioventricular block), or a specific abnormality on a heart tracing called QT prolongation (confirm with trial site)
- You (or your child) cannot take trametinib due to an allergy or sensitivity to the drug
- The child's parent or legal guardian is not willing to give consent for the child to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: MAciej Kołodziej, MD, Medical University of Warsaw
Phone: 22-317-95-37
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Effectiveness of the trametynib treatment on cardiac hyperthropy; Effectiveness of the trametynib treatment on laboratory enzymes levels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.